Replies to post #100606 on Avid Bioservices Inc (CDMO)

[geocappy1]

FTM

This is what concerns me and maybe is indicative of the dosing problem or worse, the limit of bavi's efficacy. I would love to hear your take.

In the data that KT posted, to my untrained eye it appeared that the control group had 6 survivors at 12 months, 1mg group had 10, and the 3mg group had 7. If I read that correctly, it looks like something is fishy to me (strictly logically thinking).

Could you or someone else help me out.

[Protector]

Which I think is top on and the only thing that really matters.

All the rest follows from it. For a BP doing the trial over is pocket money business certainly if they know Bavi works.

CSM will pay the past investment back in such case.

I still do not believe we'll have to do the PII all over if survival data and safety profile are OK. In a signal seeking PII survival data is a hell of a signal if it is very good. For safety we know there are not much problems with Bavi.

The rest can be re-established in PIII (unfortunately only with one dose type).